Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer

PURPOSE: Contemporary treatment for metastatic hormone sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT) plus abiraterone or docetaxel. While these intensified regimens have improved efficacy, they are also associated with increased cost and toxicities. Not all men with m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Urol Oncol
Autors principals: Hahn, Andrew W., Stenehjem, David D., Alex, Anitha B., Gill, David M., Cheng, Heather H., Kessler, Elizabeth R, Chittoria, Namita, Twardowski, Przemyslaw, Vaishampayan, Ulka, Agarwal, Neeraj
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857455/
https://ncbi.nlm.nih.gov/pubmed/30770300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2019.01.029
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars